This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Taltz
  • /
  • Pharmacokinetic Evaluations of Ixekizumab Followin...
Clinical trial

Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis

Read time: 2 mins
Last updated:13th Mar 2013
Identifier: NCT01777191
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.

 

Category Value
Date last updated at source 2016-09-13
Study type(s) Interventional
Expected enrolment 204
Study start date 2013-03-13
Estimated primary completion date 2015-05-01

View full details